The U.S. Court of Appeals for the Federal Circuit upheld a patent validity decision in a dispute between Parse Biosciences and 10x Genomics. The appeals court affirmed that three 10x Genomics patents covering methods for analyzing nucleic acids from single cells were invalidated as obvious by the U.S. Patent Trial and Appeal Board. Parse Biosciences—acquired by Qiagen in late 2025—challenged the claims via inter partes reviews, with the PTAB finding them “unpatentable as obvious” in early 2025. 10x appealed, and the Federal Circuit’s ruling maintained that invalidation. The decision was reported as not affecting a separate district court ruling from the District of Delaware that invalidated a different Scale Biosciences patent, which had been tied to the now-10x portfolio through a prior acquisition.